Insider Buying: Korro Bio (NASDAQ:KRRO) Major Shareholder Purchases $2,300,881.00 in Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Rick Yang bought 207,100 shares of the stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the transaction, the insider owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. The trade was a 18.99% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Price Performance

Shares of Korro Bio stock opened at $12.80 on Friday. The firm’s fifty day simple moving average is $10.99 and its 200-day simple moving average is $20.18. Korro Bio, Inc. has a 12 month low of $5.20 and a 12 month high of $55.89. The stock has a market capitalization of $120.58 million, a price-to-earnings ratio of -1.03 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). Korro Bio had a negative return on equity of 99.63% and a negative net margin of 1,834.48%.The business had revenue of $1.29 million for the quarter, compared to analyst estimates of $0.43 million. Analysts anticipate that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Institutional Trading of Korro Bio

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new stake in shares of Korro Bio in the third quarter valued at about $39,000. Wells Fargo & Company MN raised its holdings in Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after purchasing an additional 2,352 shares in the last quarter. Guggenheim Capital LLC acquired a new stake in Korro Bio in the fourth quarter valued at about $84,000. Jain Global LLC acquired a new stake in Korro Bio in the fourth quarter valued at about $85,000. Finally, Deutsche Bank AG boosted its holdings in Korro Bio by 241.9% in the 4th quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after purchasing an additional 9,027 shares in the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KRRO. Cantor Fitzgerald increased their target price on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Friday. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Thursday, January 29th. Wall Street Zen cut Korro Bio from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Clear Str upgraded Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

More Korro Bio News

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.